$IBRX watching IBRX strictly through a urology lens has been fascinating. Anktiva has gone from something we mentioned at conferences to something we’re using in practice. So whether you’re bullish or bearish on the stock itself, the next debate isn’t “does it work“ it’s how much adoption and label expansion. It will ultimately earn.
View on X ↗